CRSP vs MTD · rev $11.6M vs P/E 27, rev $1.97B
Crispr Therapeutics AG (CRSP) versus Mettler-Toledo International Inc (MTD) — a side-by-side from cached financials, not a winner call.
Crispr Therapeutics AG (CRSP) is a biotechnology company listed on US.
Mettler-Toledo International Inc (MTD) is a diagnostics & research company listed on NYSE.
Latest reported CRSP revenue for 2026-06-30 was $11.6M. Net income was -$214.1M. CRSP currently screens at market cap $5.42B.
Latest reported MTD revenue for 2026-06-30 was $1.97B. Net income was $402.4M. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
CRSP currently screens at market cap $5.42B. MTD currently screens at market cap $23.20B and trailing P/E 26.9.
Not investment advice. Open the CRSP and MTD stock pages for the full models.
Not investment advice.